Compare Novartis AG (NVS) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Wheaton Precious Metals Corp — how do they compare? Novartis AG trades at $139.5 (market cap $262.64B), while Wheaton Precious Metals Corp trades at $157.31 (market cap $70.35B). The key difference: Novartis AG is far larger — about 3.7× Wheaton Precious Metals Corp's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | WPM | |
|---|---|---|
Market Cap | $262.64B | $70.35B |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $165.72 |
52-Week Low | $121.80 | $94.37 |
Enterprise Value | $303.97B | $72.23B |
Dividend Yield | 3.44% | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $1.19 versus $1.15 expected, and record revenue of $2.31 billion in 2025 underscore robust operational momentum. The company's royalty and streaming model continues to deliver high margins, with a net income margin of 64.66% in 2025.
The outlook remains positive, supported by an 80% analyst buy rating and a consensus price target of $161.75, though risks include exposure to commodity price volatility and significant capital expenditures projected for 2026. The stock's current valuation multiples, such as a P/E of 34.41, reflect premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
